<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505567</url>
  </required_header>
  <id_info>
    <org_study_id>RT1-01US</org_study_id>
    <nct_id>NCT03505567</nct_id>
  </id_info>
  <brief_title>Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100</brief_title>
  <acronym>OCT</acronym>
  <official_title>Pilot Comparative Study of the Kowa OCT Bi-μ and the Optovue iVue 100</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective comparative study to gather pilot agreement and precision data in&#xD;
      normal subjects, subjects with glaucoma, and subjects with retinal disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2018</start_date>
  <completion_date type="Actual">September 1, 2018</completion_date>
  <primary_completion_date type="Actual">September 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Eligible participants assigned two interventions under random sequence assignments.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare KOWA OCT Bi-μ and Optovue iVue 100</measure>
    <time_frame>1-2 days</time_frame>
    <description>Full retinal thickness [Early Treatment Diabetic Retinopathy Study (ETDRS) Grid]&#xD;
Full retinal thickness (Manual Measurement)&#xD;
Retinal nerve fiber layer thickness&#xD;
Ganglion cell complex thickness&#xD;
Full retinal thickness map</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Evaluate any adverse events found during the clinical study</measure>
    <time_frame>1-2 days</time_frame>
    <description>Evaluate any adverse events found during the clinical study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Glaucoma</condition>
  <condition>Retinal Disease</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Random Sequenced Interventions</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants from three condition groups (normal, glaucoma, retinal disease) assigned two interventions (Kowa OCT Bi-μ and the Optovue iVue 100) under random sequence assignments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KOWA OCT Bi-µ</intervention_name>
    <description>Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.</description>
    <arm_group_label>Random Sequenced Interventions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optovue iVue 100</intervention_name>
    <description>U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100</description>
    <arm_group_label>Random Sequenced Interventions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Normal Group):&#xD;
&#xD;
          -  Subjects with normal eye examinations (without pathology other than cataract) in one&#xD;
             or both eyes on the date of the study visit;&#xD;
&#xD;
          -  Subjects with intraocular pressure (IOP) ≤ 21 mmHg in the normal eye(s) on the date of&#xD;
             the study visit; and&#xD;
&#xD;
          -  Subjects with current best-spectacle-corrected visual acuity (BSCVA) of 20/40 or&#xD;
             better in the normal eye(s) on the date the study visit.&#xD;
&#xD;
        Exclusion Criteria (Normal Group):&#xD;
&#xD;
          -  Subjects unable to tolerate ophthalmic imaging;&#xD;
&#xD;
          -  Subjects with ocular media not sufficiently clear to obtain acceptable OCT images;&#xD;
&#xD;
          -  Subjects with any current ocular pathology other than cataract in the normal eye(s),&#xD;
             as determined by self-report and/or investigator assessment at the study visit;&#xD;
&#xD;
          -  Subjects with current narrow anterior chamber drainage angle in the normal eye(s), as&#xD;
             determined by self-report and/or investigator assessment at the study visit; and&#xD;
&#xD;
          -  Subjects with a history of leukemia, dementia or multiple sclerosis.&#xD;
&#xD;
        Inclusion Criteria (Glaucoma Group):&#xD;
&#xD;
          -  Subjects who have been diagnosed with glaucoma in the glaucoma study eye(s), with&#xD;
             optic nerve damage as evidenced by either of the following optic disc or retinal nerve&#xD;
             fiber layer structural abnormalities observed via fundus exam during the study visit:&#xD;
&#xD;
               1. Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially&#xD;
                  at the inferior or superior poles with or without disc hemorrhage; or&#xD;
&#xD;
               2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural&#xD;
                  tissue;&#xD;
&#xD;
          -  Subjects with a current BSCVA of 20/40 or better in the glaucoma study eye(s) on the&#xD;
             date of the visit; and&#xD;
&#xD;
          -  History of visual field defects within the previous two (2) months from the study&#xD;
             visit or measured on the day of the study visit that is consistent with glaucomatous&#xD;
             optic nerve damage based on at least one of the following findings:&#xD;
&#xD;
               1. On pattern deviation (PD), there exists a cluster of 3 or more points in an&#xD;
                  expected location of the visual field depressed below the 5% level, at least 1 of&#xD;
                  which is depressed below the 1% level; and&#xD;
&#xD;
               2. Glaucoma hemi-field test &quot;outside normal limits.&quot;&#xD;
&#xD;
        Exclusion Criteria (Glaucoma Group):&#xD;
&#xD;
          -  Subjects unable to tolerate ophthalmic imaging;&#xD;
&#xD;
          -  Subjects with ocular media not sufficiently clear to obtain acceptable OCT images;&#xD;
&#xD;
          -  Subjects with at least one Humphrey Field Analyzer (HFA) visual field (24-2 SITA&#xD;
             Standard, white on white) measured on the day of the study visit, or within the&#xD;
             previous two (2) months from the study visit with unreliable results, defined as&#xD;
             fixation losses &gt; 20%, or false positives &gt; 33%, or false negatives &gt; 33% in the&#xD;
             glaucoma study eye(s);&#xD;
&#xD;
          -  Subjects with any current ocular pathology except glaucoma in the glaucoma study&#xD;
             eye(s), as determined by self-report and/or investigator assessment on the day of the&#xD;
             study visit; and&#xD;
&#xD;
          -  Subjects with a history of leukemia, dementia or multiple sclerosis.&#xD;
&#xD;
        Inclusion Criteria (Retinal Disease Group):&#xD;
&#xD;
          -  Subjects with current IOP ≤ 21 mmHg in the retinal disease study eye(s) on the day of&#xD;
             the study visit;&#xD;
&#xD;
          -  Subjects with a current BSCVA of 20/400 or better in the retinal disease study eye(s)&#xD;
             at the study visit; and&#xD;
&#xD;
          -  Subjects diagnosed with retinal pathology including but not limited to: Macular&#xD;
             Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal&#xD;
             Membrane, Cystoid Macular Edema, and others in the retinal disease study eye(s) as&#xD;
             confirmed within the past six (6) months.&#xD;
&#xD;
        Exclusion Criteria (Retinal Disease Group):&#xD;
&#xD;
          -  Subjects unable to tolerate ophthalmic imaging;&#xD;
&#xD;
          -  Subjects with ocular media not sufficiently clear to obtain acceptable OCT images;&#xD;
&#xD;
          -  Subjects with glaucoma or any ocular pathology other than retinal pathology (e.g.&#xD;
             cornea pathology) in the retinal disease study eye(s), as determined by self-report&#xD;
             and/or investigator assessment at the study visit;&#xD;
&#xD;
          -  Subjects with current narrow anterior chamber drainage angle in the retinal disease&#xD;
             study eye(s), as determined by self-report and/or investigator assessment at the study&#xD;
             visit; and&#xD;
&#xD;
          -  Subjects with a history of leukemia, dementia or multiple sclerosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hosford, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Kowa Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>September 7, 2018</last_update_submitted>
  <last_update_submitted_qc>September 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

